In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599
- 1 January 2004
- journal article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 10 (3) , 146-156
- https://doi.org/10.1007/s10156-004-0309-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological propertiesBioorganic & Medicinal Chemistry, 2003
- In Vitro and In Vivo Pharmacokinetics-Pharmacodynamics of GV143253A, a Novel TrinemAntimicrobial Agents and Chemotherapy, 2003
- Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureusJournal of Clinical Microbiology, 2003
- Linezolid resistance in a clinical isolate of Staphylococcus aureusThe Lancet, 2001
- Staphylococcus aureus Bacteremia: Predictors of 30-Day Mortality in a Large CohortClinical Infectious Diseases, 2000
- Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2000
- Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinThe Lancet, 1997
- Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1997
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997
- The Progressive Intercontinental Spread of Methicillin-Resistant Staphylococcus aureusClinical Infectious Diseases, 1997